Literature DB >> 20584771

Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette.

Jill M Williams1, Kunal K Gandhi, Shou-En Lu, Supriya Kumar, Junwu Shen, Jonathan Foulds, Howard Kipen, Neal L Benowitz.   

Abstract

INTRODUCTION: The increase in blood nicotine after smoking a single cigarette is nicotine boost. We hypothesized that smokers with schizophrenia (SCZ) have a greater nicotine boost than controls without this disorder.
METHODS: Twenty-one subjects (11 SCZ and 10 controls, CON) had repeated venous blood sampling before, during, and after smoking a single cigarette after 12-hr abstinence to measure nicotine concentrations. Blood samples were drawn at baseline (before smoking) and 1, 2, 4, 6, 8, 10, 20, 30, 60, 90, and 120 min after the first puff. Groups were similar in baseline characteristics, including gender and level of dependence, and all smoked 20-30 cigarettes/day. Area under the serum nicotine concentration-time curve (AUC(20)) was calculated for time up to 20 min after the start of smoking.
RESULTS: The mean difference in AUC(20) was significantly greater for SCZ versus CON (135.4 ng-min/ml; 95% CI = 0.45-283.80). The shape of the nicotine concentration-time curve for SCZ was significantly different compared with controls (p < .01). Nicotine boost in the first 4 min of smoking was higher in SCZ versus CON (25.2 vs. 11.1 ng/ml, p < .01) with no difference in the total time spent smoking. DISCUSSION: This technique improves on methods, which draw only two blood specimens to assess nicotine intake. Understanding how nicotine boost differs in SCZ from CON may explain high levels of addiction and low success in cessation in smokers with SCZ.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20584771      PMCID: PMC2910875          DOI: 10.1093/ntr/ntq102

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  15 in total

1.  Development and validation of the Wisconsin Smoking Withdrawal Scale.

Authors:  S K Welsch; S S Smith; D W Wetter; D E Jorenby; M C Fiore; T B Baker
Journal:  Exp Clin Psychopharmacol       Date:  1999-11       Impact factor: 3.157

2.  Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving.

Authors:  Saul Shiffman; William G Shadel; Raymond Niaura; Moise A Khayrallah; Douglas E Jorenby; Charles F Ryan; Clifford L Ferguson
Journal:  Psychopharmacology (Berl)       Date:  2003-02-25       Impact factor: 4.530

3.  Individual differences in nicotine intake per cigarette.

Authors:  Freda Patterson; Neal Benowitz; Peter Shields; Vyga Kaufmann; Christopher Jepson; Paul Wileyto; Susan Kucharski; Caryn Lerman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-05       Impact factor: 4.254

4.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.

Authors:  Delia Dempsey; Piotr Tutka; Peyton Jacob; Faith Allen; Kerri Schoedel; Rachel F Tyndale; Neal L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2004-07       Impact factor: 6.875

5.  The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation.

Authors:  S R Kay; L A Opler; J P Lindenmayer
Journal:  Br J Psychiatry Suppl       Date:  1989-11

Review 6.  Cigarette smoking: a dependence on high-nicotine boli.

Authors:  M A Russell; C Feyerabend
Journal:  Drug Metab Rev       Date:  1978       Impact factor: 4.518

7.  Development and validation of brief measures of positive and negative affect: the PANAS scales.

Authors:  D Watson; L A Clark; A Tellegen
Journal:  J Pers Soc Psychol       Date:  1988-06

8.  Tobacco use in schizophrenia: a study of cotinine concentrations in the saliva of patients and controls.

Authors:  Jan-Erik Strand; Henrik Nybäck
Journal:  Eur Psychiatry       Date:  2005-01       Impact factor: 5.361

9.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

Authors:  T F Heatherton; L T Kozlowski; R C Frecker; K O Fagerström
Journal:  Br J Addict       Date:  1991-09

10.  Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype.

Authors:  J Loughead; E P Wileyto; J N Valdez; P Sanborn; K Tang; A A Strasser; K Ruparel; R Ray; R C Gur; C Lerman
Journal:  Mol Psychiatry       Date:  2008-12-09       Impact factor: 15.992

View more
  32 in total

1.  Rapid smoking may not be aversive in schizophrenia.

Authors:  Jill M Williams; Kunal K Gandhi; Shou-En Lu; Marc L Steinberg; Neal L Benowitz
Journal:  Nicotine Tob Res       Date:  2012-02-07       Impact factor: 4.244

2.  Task persistence predicts smoking cessation in smokers with and without schizophrenia.

Authors:  Marc L Steinberg; Jill M Williams; Kunal K Gandhi; Jonathan Foulds; Elizabeth E Epstein; Thomas H Brandon
Journal:  Psychol Addict Behav       Date:  2012-05-28

Review 3.  MicroRNAs in addiction: adaptation's middlemen?

Authors:  M D Li; A D van der Vaart
Journal:  Mol Psychiatry       Date:  2011-05-24       Impact factor: 15.992

4.  Schizophrenia and the retina: Towards a 2020 perspective.

Authors:  Steven M Silverstein; Samantha I Fradkin; Docia L Demmin
Journal:  Schizophr Res       Date:  2019-11-07       Impact factor: 4.939

5.  Nicotine intake and smoking topography in smokers with bipolar disorder.

Authors:  Jill M Williams; Kunal K Gandhi; Shou-En Lu; Marc L Steinberg; Neal L Benowitz
Journal:  Bipolar Disord       Date:  2012-09       Impact factor: 6.744

6.  Neuronal effects of nicotine during auditory selective attention in schizophrenia.

Authors:  Jason Smucny; Ann Olincy; Donald C Rojas; Jason R Tregellas
Journal:  Hum Brain Mapp       Date:  2015-10-31       Impact factor: 5.038

Review 7.  Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.

Authors:  Ann Olincy; Robert Freedman
Journal:  Handb Exp Pharmacol       Date:  2012

8.  Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes.

Authors:  Gideon St Helen; Christopher Havel; Delia A Dempsey; Peyton Jacob; Neal L Benowitz
Journal:  Addiction       Date:  2015-11-11       Impact factor: 6.526

Review 9.  Reduced nicotine product standards for combustible tobacco: building an empirical basis for effective regulation.

Authors:  Eric C Donny; Dorothy K Hatsukami; Neal L Benowitz; Alan F Sved; Jennifer W Tidey; Rachel N Cassidy
Journal:  Prev Med       Date:  2014-06-23       Impact factor: 4.018

10.  Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial.

Authors:  Gladys N Pachas; Corinne Cather; Sarah A Pratt; Bettina Hoeppner; Johanna Nino; Sara V Carlini; Eric D Achtyes; Harry Lando; Kim T Mueser; Nancy A Rigotti; Donald C Goff; A Eden Evins
Journal:  J Dual Diagn       Date:  2012-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.